142 related articles for article (PubMed ID: 34107172)
1. Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.
Trivedi A; Oberoi RK; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Hutton S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1442-1451. PubMed ID: 34107172
[TBL] [Abstract][Full Text] [Related]
2. Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil.
Trivedi A; Oberoi RK; Jafarinasabian P; Zhang H; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacokinet; 2021 Aug; 60(8):1041-1048. PubMed ID: 33768487
[TBL] [Abstract][Full Text] [Related]
3. Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator.
Trivedi A; Oberoi RK; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Simiens MA; Terminello B; Abbasi S; Dutta S; Lee E
Biopharm Drug Dispos; 2021 Jul; 42(7):319-328. PubMed ID: 34087948
[TBL] [Abstract][Full Text] [Related]
4. Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects.
Trivedi A; Oberoi RK; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Dutta S; Lee E
Clin Drug Investig; 2021 Jul; 41(7):647-652. PubMed ID: 34097256
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects.
Trivedi A; Malik FI; Mackowski M; Hutton S; Aoki M; Abbasi S; Dutta S; Lee E
Eur J Drug Metab Pharmacokinet; 2021 Nov; 46(6):759-770. PubMed ID: 34415561
[TBL] [Abstract][Full Text] [Related]
6. Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects.
Trivedi A; Mackowski M; Jafarinasabian P; Zhang H; Flach S; Terminello B; Bhatia A; Dutta S; Lee E
Clin Drug Investig; 2021 Jul; 41(7):639-645. PubMed ID: 34110614
[TBL] [Abstract][Full Text] [Related]
7. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects.
Palaparthy R; Banfield C; Alvarez P; Yan L; Smith B; Johnson J; Monsalvo ML; Malik F
Int J Clin Pharmacol Ther; 2016 Mar; 54(3):217-27. PubMed ID: 26709596
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Disposition, and Biotransformation of [
Trivedi A; Wahlstrom J; Mackowski M; Dutta S; Lee E
Drug Metab Dispos; 2021 Aug; 49(8):619-628. PubMed ID: 34011533
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects.
Trivedi A; Malik FI; Jafarinasabian P; Zhang H; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):185-193. PubMed ID: 34145992
[TBL] [Abstract][Full Text] [Related]
10. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of drug-drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically-based pharmacokinetic model.
Trivedi A; Sohn W; Kulkarni P; Jafarinasabian P; Zhang H; Spring M; Flach S; Abbasi S; Wahlstrom J; Lee E; Dutta S
Clin Transl Sci; 2021 Nov; 14(6):2510-2520. PubMed ID: 34415673
[TBL] [Abstract][Full Text] [Related]
12. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects.
Trivedi A; Sohn W; Hsu CP; Jafarinasabian P; Zhang H; Hutton S; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Mar; 11(3):388-396. PubMed ID: 34634185
[TBL] [Abstract][Full Text] [Related]
14. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; O'Gorman M; Tripathy S; Dowty ME; Wang L; Malhotra BK
J Clin Pharmacol; 2021 Oct; 61(10):1311-1323. PubMed ID: 33749838
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects.
Trivedi A; Sohn W; Jafarinasabian P; Zhang H; Terminello B; Flach S; Abbasi S; Dutta S; Lee E
Clin Pharmacol Drug Dev; 2022 Jan; 11(1):129-133. PubMed ID: 34272833
[TBL] [Abstract][Full Text] [Related]
16. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study.
Felker GM; Solomon SD; McMurray JJV; Cleland JGF; Abbasi SA; Malik FI; Zhang H; Globe G; Teerlink JR;
Circ Heart Fail; 2020 Dec; 13(12):e007814. PubMed ID: 33176437
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
[TBL] [Abstract][Full Text] [Related]
18. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.
Teerlink JR; Felker GM; McMurray JJV; Ponikowski P; Metra M; Filippatos GS; Ezekowitz JA; Dickstein K; Cleland JGF; Kim JB; Lei L; Knusel B; Wolff AA; Malik FI; Wasserman SM;
J Am Coll Cardiol; 2016 Mar; 67(12):1444-1455. PubMed ID: 27012405
[TBL] [Abstract][Full Text] [Related]
19. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.
Planelles-Herrero VJ; Hartman JJ; Robert-Paganin J; Malik FI; Houdusse A
Nat Commun; 2017 Aug; 8(1):190. PubMed ID: 28775348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
